The Protein Brewery—which has just secured the green light to market its novel mycelium ingredient in the EU—has been advised by the FDA to withdraw its GRAS notice in the US due to deficiencies in its application. However, CEO Thijs Bosch tells AgFunderNews the temporary setback will not derail its US plans as it raises an €18 million ($20.5 million) Series B extension. The Dutch startup, which m...